Abstract 42TiP
Background
HBI-8000 also known as tucidinostat is an orally bioavailable, low-nanomolar inhibitor of cancer-associated histone deacetylase enzymes. HBI-8000 is a histone deacetylase inhibitor (HDACi), and as an epigenetic regulator modulating the gene expression, without changing the DNA sequence. HBI-8000 is being developed as a monotherapy for the treatment of hematological malignancies and in combinations for the treatment of solid tumors such as melanoma, breast, kidney, and lung cancers.
Trial design
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study of HBI-8000 or Placebo combined with nivolumab in patients with unresectable or metastatic melanoma not previously treated with program cell death protein 1 (PD-1) or programmed cell death-ligand 1 (PD-L1) Inhibitors (NCT04674683). Approximately 480 patients (including approximately 30 patients in special open-label, non-randomized cohort who are either adolescents ≥12 years of age or patients with new, progressive brain metastasis) with metastatic or unresectable melanoma who have not received anti-PD-1 or anti-PD-L1 for their disease will be enrolled. Eligible patients will be randomized within appropriate stratum at a ratio of 1:1 stratified by PD-L1 expression (positive, ≥1% expression level versus negative, <1% expression level) and lactate dehydrogenase (LDH) level (normal versus elevated). Patients will be treated with one of the following: Test arm: HBI-8000 30 mg oral twice a week (BIW) + nivolumab 480 mg intravenous (IV) every 4 weeks (Q4W) Control arm: Placebo oral BIW + nivolumab 480 mg IV Q4W The study began enrolling patients in August 2021 and is ongoing in 13 countries including Australia, Austria, Belgium, Brazil, Czech Republic, France, Germany, Italy, New Zealand, South Africa, Spain, United Kingdom and United States of America.
Clinical trial identification
NCT04674683.
Legal entity responsible for the study
HUYA Bioscience International.
Funding
HUYA Bioscience International.
Disclosure
F. Shojaei, J. Ning, L. Aiyer, M. Gillings, F. Kabbinavar: Financial Interests, Personal, Full or part-time Employment: HUYA Bioscience International. All other authors have declared no conflicts of interest.
Resources from the same session
16P - The prognostic value of androgen receptor expression in triple-negative breast cancer patients
Presenter: Rasha Haggag
Session: Poster viewing 01
17P - Clinical, pathological complete response and prognosis characteristics of HER2-low breast cancer in neoadjuvant chemotherapy setting: A retrospective analysis
Presenter: Hui Liu
Session: Poster viewing 01
18P - Low levels of miR-18a is associated with immunosuppression and increased chemo-unresponsiveness in ER-negative tumors
Presenter: Madhumathy Nair
Session: Poster viewing 01
19P - Cardiac and lung sparing radiotherapy in breast and chest wall irradiation with surface guided radiotherapy using deep inspiratory breath hold technique
Presenter: Ravi Shankar Bellala
Session: Poster viewing 01
20P - Physician perceptions to use of trastuzumab in HER2+ breast cancer in India
Presenter: Nagendra Ramanjinappa
Session: Poster viewing 01
23P - Combination chemotherapy and hormone therapy (CHT) in patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): A single-centre retrospective analysis
Presenter: Kripa Bajaj
Session: Poster viewing 01
24P - Outcomes of patients with HER2 positive metastatic breast cancer treated with low dose or metronomic lapatinib
Presenter: Sherin Mathew
Session: Poster viewing 01
25P - Absolute lymphocyte count as prognostic factor in patients with metastatic breast cancer: A systematic review and meta-analysis
Presenter: Dhea Hermanto
Session: Poster viewing 01
26P - Circulating osteocalcin-positive cells, as a novel biomarker for monitoring the therapeutic effects on bone metastasis
Presenter: Min Joo Kim
Session: Poster viewing 01
27P - Outcomes analysis of the effect of an educational activity on the knowledge and confidence of oncologists regarding emerging antibody drug conjugates for the treatment of breast cancer
Presenter: Nabil Dorkhom
Session: Poster viewing 01